NetworkNewsBreaks – Mydecine Innovations Group (
Post# of 160
(Total Views: 184)
Posted On: 01/24/2022 3:31:23 PM
NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King’s College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly. “During my 31 years as a medical officer and psychiatrist in the Canadian Armed Forces, I have seen first hand the impact PTSD has on our vets and their families. Sadly, many soldiers and veterans do not respond to the evidence-based treatments readily available to them and the search is on for new safe and effective treatments. Our troops fight and sacrifice together, so it only makes sense that we help them heal together.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King’s College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly. “During my 31 years as a medical officer and psychiatrist in the Canadian Armed Forces, I have seen first hand the impact PTSD has on our vets and their families. Sadly, many soldiers and veterans do not respond to the evidence-based treatments readily available to them and the search is on for new safe and effective treatments. Our troops fight and sacrifice together, so it only makes sense that we help them heal together.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)